clinical trial

Soleno Therapeutics faces class action lawsuit over allegedly undisclosed fluid retention safety issues with DCCR drug candidate during March-November 2025 period.

$ADGM surges 11.92% after FULCRUM-VT trial shows 84% shock freedom, 59% arrhythmia freedom, supporting FDA Premarket Approval pathway for vCLAS ablation system.

Altimmune closed a $225M oversubscribed public offering led by Deep Track Capital. Proceeds will fund Phase 3 MASH trial initiation in H2 2026 and operational runway through data readout.

Fulcrum Therapeutics reports positive pociredir data in sickle cell disease, plans registration trial in H2 2026, maintains $333.3M cash runway through 2029.

Finnish pharma $ORION reported 17.8% Q1 revenue growth to €417.7M, raised full-year guidance citing Nubeqa royalties and pipeline progress.

Geron Corporation will report Q1 2026 results on May 6, advancing its approved telomerase inhibitor RYTELO and Phase 3 myelofibrosis trial.

Soleno Therapeutics faces securities litigation alleging undisclosed DCCR safety risks during March-November 2025. Lead plaintiff deadline: May 5, 2026.

Kyverna's miv-cel shows statistically significant benefits across all endpoints in stiff person syndrome trial, with 81% achieving meaningful walking speed improvement.

Class action lawsuit filed against $SLNO for alleged misstatements about diazoxide choline safety and efficacy. Lead plaintiff deadline: May 5, 2026.

Perspective Therapeutics reports 43% response rate for neuroendocrine tumor therapy with no serious safety issues, planning 2026 regulatory submissions.

Immunocore's KIMMTRAK doubled five-year survival in metastatic uveal melanoma, achieving 16% vs. 8% control rate—longest T cell engager follow-up in solid tumors.

Rosen Law Firm alerts $SLNO investors of May 5, 2026 deadline in securities class action alleging false statements about DCCR drug candidate safety risks.

Sanofi's Nuvaxovid shows 50% fewer severe side effects than Moderna's mRNA vaccine in clinical trial, with patients twice as likely to choose it again.

Sanofi's protein-based COVID-19 vaccine demonstrated significantly lower side effects than Moderna's mNEXSPIKE in head-to-head trial of 1,000 adults.

Lexicon Pharmaceuticals' pilavapadin shows promise in diabetic neuropathic pain study, supporting 10mg dose selection for Phase 3 trials.

MeiraGTx acquires J&J's bota-vec gene therapy for rare blindness in $25M deal, targeting 2027 launch with promising Phase 3 clinical data.

Arcutis reports Q1 2026 results May 6 as company presents new Phase 2 pediatric atopic dermatitis data at dermatology conference.

Tonix Pharmaceuticals publishes peer-reviewed pharmacokinetic data for TONMYA, the first new fibromyalgia treatment in 15 years, showing rapid absorption and superior bioavailability.

Portnoy Law Firm launches class action against $SLNO for allegedly concealing safety issues with lead drug DCCR, citing 27% stock plunge following patient death disclosure.

Neomorph closes $100M Series B led by Deerfield Management to advance NEO-811, its molecular glue degrader for kidney cancer, and expand its pipeline.